Investor directory

3B Ventures

3B Ventures, founded in 2017 and based in Copenhagen, Denmark, operates as a traditional non-venture capital entity focused on fostering innovation. The company supports entrepreneurs who aim to create market-disrupting enterprises while addressing one or more of the Sustainable Development Goals established by the United Nations. By leveraging artificial intelligence and a data-driven approach, 3B Ventures identifies investment opportunities and selects startups based on extensive data points gathered from a global network of partners. The firm emphasizes a commitment to making a noticeable difference through its funding decisions, concentrating on technology companies primarily in the Nordic and Southeast Asian regions.
http://3bvc.com
https://crunchbase.com/organization/3b-ventures
https://linkedin.com/company/3b-ventures
https://pitchbook.com/profiles/investor/226214-11
https://twitter.com/3b_vc
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=574291302
https://www.privateequityinternational.com/database/#/profile?id=19078

Andrew Tan

Fund Manager

1 past transactions

AnaCardio

Series A in 2022
AnaCardio is a clinical stage biopharmaceutical company focused on developing innovative drugs for the treatment of heart failure. The company's therapeutics aim to enhance the contractility of the heart muscle through a unique mechanism that utilizes a therapeutic peptide. This approach is designed to avoid common adverse effects associated with traditional treatments, such as tachycardia, arrhythmia, ischemia, or hypotension. By improving cardiac output safely, AnaCardio's drugs have the potential to enhance organ function, elevate quality of life, increase functional capacity, and lower the risks of hospitalization and mortality for patients suffering from heart failure.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.